Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Melanoma With Wild-type p53 and Detectable S100B Using Pentamidine: a Phase II Trial With Correlative Biomarker Endpoints

NCT00729807 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT00729807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00729807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Melanoma With Wild-type p53 and Detectable S100B Using Pentamidine: a Phase II Trial With Correlative Biomarker Endpoints
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2008
Completion date
November 30, 2012
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)